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Expression of the chemokine receptor chemokine C-X-C motif receptor 4 (CXCR4) plays an 
important role in cancer metastasis, autoimmune diseases and during stem cell based repair 
processes after stroke and myocardial infarction. Previously reported positron emission 
tomography (PET) imaging agents targeting CXCR4 suffer from either high non-specific uptake or 
only bind to the human form of the receptor. The objective of this study is to develop a high 
stability copper-64 labelled small molecule PET agent for imaging both human and murine CXCR4 
chemokine receptors. Methods: Synthesis, radiochemistry, stability and radioligand binding 
assays were performed for the novel tracer 64Cu-CuCB-Bicyclam. In vivo dynamic PET studies 
were carried out on mice bearing U87 (CXCR4low) and U87.CXCR4 (CXCR4high) tumors. 
Biodistribution and receptor blocking studies were carried out on CD1-IGS immunocompetent 
mice. CXCR4 expression on tumor and liver disaggregates was confirmed using a combination of 
immunohistochemistry, quantitative polymerase chain reaction (qPCR) and western blot. Results: 
64Cu-CuCB-Bicyclam has a high affinity for both the human and murine variants of the CXCR4 
receptor (IC50 = 8 nM (human)/ 2 nM (murine)) and can be obtained from the parent chelator 
that has low affinity. In vitro and in vivo studies demonstrate specific uptake in CXCR4 expressing 
cells that can be blocked by >90% using a higher affinity antagonist, with limited uptake in non-
CXCR4 expressing organs and high in vivo stability. The tracer was also able to selectively displace 
the CXCR4 antagonists AMD3100 and AMD3465 from the liver. Conclusions: The application of 
the tetraazamacrocyclic small molecule 64Cu-CuCB-Bicyclam is demonstrated as an imaging agent 
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for the CXCR4 receptor that is likely to be applicable across a range of species. It has high affinity 
and stability and is suitable for preclinical research in immunocompetent murine models. 
Keywords: CXCR4, copper-64, azamacrocycle, cyclam, AMD3100.  
  




Chemokine C-X-C motif receptor 4 (CXCR4) is a seven-transmembrane helix G-protein coupled 
receptor. The interaction of CXCR4 with its cognate ligand, stromal cell-derived factor 1 (SDF1-
/ CXCL12), is essential during embryonic development and plays a key role in normal 
physiological function, including control of hematopoietic cells during homeostasis (1). CXCR4 is 
overexpressed in multiple cancer types, with expression levels associated with increased 
proliferation, migration and survival (2,3). In addition, CXCR4 expression on circulating tumor 
cells has been shown to enable metastasis to CXCL12 expressing organs including liver, lung and 
bone marrow (4) and inhibition of CXCR4-CXCL12 signalling reduces metastasis in various breast 
cancer models (5). There is a clear role in multiple myeloma, particularly in extra-medullary 
disease, a sub-type with poor prognosis that is chemotherapy resistant (6,7).  Important links 
have been elucidated between CXCL12 and immunotherapies where blocking the signalling axis 
prevented recruitment of immunosuppressing fibroblast activation protein positive stromal cells 
(8).  CXCR4 has also been shown to have a role in stroke, autoimmune disease (9,10) and 
myocardial infarction, with CXCL12 upregulated post-infarction (11-13). CXCR4 is therefore a 
candidate prognostic biomarker for a number of clinical indications; as a number of CXCR4 
targeted agents are currently in clinical trials, it also has potential as a predictive biomarker to 
enable patient stratification. 
 The gallium-68 radiolabelled cyclic peptide CPCR4.2 (14,15), Pentixafor, has been used to 
demonstrate the potential of CXCR4 positron emission tomography (PET) imaging over the past 
few years. Pentixafor has been used clinically to image human CXCR4 expression in a range of 
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cancer types including, lymphoma, multiple melanoma, glioblastoma and small cell lung cancer 
in proof of concept studies (16-21). However, Pentixafor has little or no binding affinity to the 
murine variant of CXCR4 (18), limiting assessment of non-xenogenic CXCR4 expression in 
preclinical models.  
Small molecule CXCR4 antagonists based on tetraazamacrocycles, including AMD3100 
and AMD3465(22) (Supplemental Fig. 1), bind to both human and mouse variants of the receptor 
(23-26), with AMD3100 the sole CXCR4 antagonist currently US Food and Drug Administration 
and the European Medicines Agency approved for human use. The cyclam components of these 
molecules allow for transition metal complex formation, which switches the binding mode from 
electrostatic/ H-bonding between the protonated cyclam amine groups and aspartate residue 
side chains (171 and 262) to coordinate bonds with the same residues. Direct labelling with 
copper-64 to enable PET imaging has been attempted (27-30), and whilst CXCR4-dependent 
tumor uptake of 64Cu-CuAMD3100 and 64Cu-CuAMD3465 (Supplemental Fig. 1) has been 
demonstrated, high non-specific hepatic accumulation (likely caused by complex instability) 
prevented further development of these compounds (28,29). Copper(II) cyclam complexes are 
unlikely to have sufficient kinetic stability to retain the metal ion in vivo (31-38).  
Configurational restriction of the cyclam with an ethylene cross-bridge confers kinetic 
stability on the copper(II) complex and increases affinity for/residence time at the CXCR4 
receptor. The ethylene bridge in the macrocyclic rings of CB-bicyclam (Fig. 1B) allows only one 
configuration for the macrocycle copper(II) complex which optimises coordinate bond formation 
with CXCR4 residues relative to non-bridged cyclam metal complexes of AMD3100 (37,39-44).  
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The unbridged macrocycle complexes are in equilibrium between up to six possible 
configurations, leading to a stochastic overall affinity reflective of the average of these states. 
The affinity increase is likely mediated by reduction in bond lengths (effectively switched from 
axial to equatorial) to give shorter, stronger coordination bonds to CXCR4 receptor surface 
aspartate residues (39,40).  
We have developed an understanding of structure activity relationships of CXCR4 binding 
bridged azamacrocyclic compound and set out to apply this knowledge to development of PET 
imaging probes.  Currently, there are no blockable and stable nuclear imaging agents which bind 
to both human and non-human variants of CXCR4; inhibiting research in syngeneic models or 
understanding the role of CXCR4 in developmental pathways (45). In this work, we investigate a 
copper-64 labelled tetraazamacrocyclic small molecule CXCR4 antagonist, which has suitable 
characteristics (biodistribution, specificity and stability) for imaging both the human and murine 
homologues of the CXCR4 receptor. 
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MATERIALS AND METHODS 
Ethics 
All animal procedures were approved by the University of Hull Animal Welfare Ethical 
Review Body and carried out in accordance with the United Kingdom’s Guidance on the 
Operation of Animals (Scientific Procedures) Act 1986 and the UKCCCR Guidelines 2010 (Home 
Office Project License number 60/4549) (46).  
General 
All chemicals were supplied by Sigma-Aldrich (UK) unless otherwise stated and used as 
supplied. Elemental analysis was performed using a CHN analyser EA1108 (Carlo Erba). Accurate 
mass spectrometry measurements were obtained using a LQT Orbitrap XL. Semi-preparative high 
performance liquid chromatography was carried out using an Agilent 1100 series equipped with 
a Ultraviolet light detector (series G1314A) and a NaI radiodetector. Thin layer chromatography 
was carried out using neutral alumina sheets (Merck USA), eluting with methanol 95:5 water, 
saturated with excess NaCl. Radio-TLC was carried out using a Lablogic ScanRam, equipped with 
a NaI detector at a speed of 10 mm/min. Data were recorded using Lablogic Laura (version 
4.1.13.91). Copper-64 was purchased from the University of Cambridge. Further details of 
synthesis, radiochemistry and stability methodologies are present in the supplemental 
information (Supplemental Figs. 2 and 3). 64Cu-CuAMD3100 was synthesized and analysed 
following the reported procedure (27).  




The U87 cell line was purchased from American Type culture Collection, the glioblastoma 
astrocytoma U87.CD4 cell line was transfected with CXCR4 (human) or CXCR4 (murine). Both U87 
and U87.CXCR4 (human and murine) cells were grown in Dulbecco's modified Eagle's medium 
with L-Glutamine medium (Lonza, Belgium) with U87.CXCR4 supplemented with 2 µg/ml 
puromycin. All cell lines were cultured in the presence of 10% foetal bovine serum, in a 
humidified incubator with 5% CO2. The intracellular calcium mobilization in response to CXCL12 
was measured in U87.CXCR4 (human) cell lines at 37°C by monitoring the fluorescence of an 
intracellular calcium probe (Fig. 1A) as a function of time using a Fluorometric Imaging Plate 
Reader (FLIPR; Molecular Devices, Sunnyvale USA) (40,47) with compounds (AMD3100, 
CuAMD3100, CB-Bicyclam, CuCB-Bicyclam, Cu2CB-Bicyclam) tested in the concentration range 
0.01-10,000 nM . Flow cytometry was carried out as previously described using a FACSCalibur 
(Becton Dickinson USA) and data were analysed using Cellquest software (39). CXCR4 expression 
was determined by western blot, immunohistochemistry (as previously described) (15,28) and 
quantitative polymerase chain reaction (qPCR) as previously described (Supplemental Table 1). 
Receptor Binding Assay 
U87.CXCR4 (human) cells grown to 60% to 80% confluence were used for receptor binding 
assays. Cells were washed with cold PBS buffer and flasks were placed on ice to prevent receptor 
internalization. Cells were detached using a cell scraper, centrifuged at 200 g for 5 minutes and 
then 5x105 cells were resuspended with cold PBS buffer. Cells were incubated with 37 kBq/mL 
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(5.2 nM) of 64Cu-CuCB-Bicyclam in PBS for 60 minutes at 4C. After incubation, cells were washed 
quickly three times with cold PBS and cell-associated radioactivity was determined in using an 
automatic gamma counter (Wizard 3’ Wallac, UK).  
For blocking experiments, cells were preincubated with 20 µM of Cu2CB-Bicyclam for 1 h prior to 
washing three times in cold PBS buffer and incubation with radiotracer as above. Data is 
expressed as % incubated dose (%) ± SEM, representing the mean of three independent 
experiments with three internal repeats.  
Animal Models 
Female CD1-IGS (Crl: CD1 (IGS)) and CD1-Nude (Crl:CD1-Foxn1Nu) mice (age 21-27 days; 
weight 20-25 g) were purchased from Charles River Laboratories. CD1-Nude mice were 
subcutaneously (s.c.) implanted with a 5x106 cells/100 µL suspension of U87/U87-human CXCR4 
cells in Geltrex basement membrane in the upper flank, under anaesthesia. Tumor sizes were 
measured every 2 days using calipers, and tumor volume was determined by using the equation 
length*width*height (to give volume in mm3).  
PET/CT Imaging and Analysis 
Dynamic whole body PET and CT images were acquired on the Sedecal SuperArgus 2R PET 
scanner (Sedecal, Spain). Mice were induced with 5% isoflurane/oxygen (v/v) anaesthesia before 
maintenance at 2%, using a flow rate of 1 L/min. Mice were cannulated in the tail vein using a 
bespoke catheter before being placed into an imaging cell where temperature and respiration 
were monitored (Minerve, France). 64Cu-CuCB-Bicyclam (8.9 ± 3.2 MBq, 7.15 GBq/mol, 1.2 nmol) 
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was injected at the beginning of a 90 minute dynamic imaging sequence (10 frames: 3x 120 s, 1x 
240 s, 4x 600 s and 2x 1200 s). Mice were maintained at 1% anaesthesia during scanning, with 
temperature and respiration monitored throughout. Following the PET scan, a CT image was 
acquired for anatomic co-registration (40 kV, 140 µA, 360 projections, 8 shots). 
For specificity studies, a separate group of mice were injected with a blocking dose of 5 
mg/kg of Cu2CB-Bicyclam administered intraperitoneally 60 minutes prior to injection of 64Cu-
CuCB-Bicyclam. 
PET emission data were reconstructed using an 3D ordered subset expectation 
maximisation (OSEM3D) algorithm with corrections for randoms, scatter and attenuation. Data 
were analysed using AMIDE (48) and Vivoquant software (InVicro, Boston, USA), with regions of 
interest (ROI) drawn over tumors and various tissues to generate time activity curves. 
Standardized uptake values (SUV) were obtained after correction for injected dose and animal 
weight. Tumor and liver samples were taken at sacrifice and fixed in formalin/frozen in liquid 
nitrogen. 
Ex vivo Biodistribution, Urine Stability and Blocking studies 
CD1-IGS mice were injected intra-peritoneally with 5 mg/kg of Cu2CB-Bicyclam, CuCB-
Bicyclam, AMD3100 or AMD3465 in saline. For control experiments, no blocking injection was 
given. At 60 minutes after blocking, mice were injected i.v. with ~740 kBq of 64Cu-CuCB-Bicyclam 
(or 64Cu-AMD3100) in the tail vein, and this stock solution was used to calibrate the automatic 
gamma counter (Wizard 3’’ Wallac, UK). 90 minutes post- tracer injection, blood, brain, heart, 
plasma, muscle, lungs, thymus, bone, spleen, nose, kidney, liver and intestines were collected 
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after sacrifice and dissection. Radioactivity within tissue samples was counted using the 
automatic gamma counter and counts per minute for each tissue sample were normalized to the 
total injected dose of radioactivity and weight of tissue to give the radioactivity uptake as %ID/g. 
Before sacrifice, urine was collected and analysed using radio-TLC using the same QC method as 
during synthesis to determine stability (27). 
 
Data Analysis 
Tumor uptake between CXCR4high and CXCR4low expressing tumors was compared via 
unpaired two-tailed t-test. Tumor and liver uptake was compared in blocked and non-blocked 




Synthesis and Characterisation 
The formation of the non-radioactive analogue CuCB-Bicyclam was carried out by reacting 
the previously described CB-Bicyclam with a stoichiometric amount of copper(II) acetate to form 
the mono-copper derivative, after which analytically pure samples were obtained using size 
exclusion chromatography (Supplemental Fig. 2). In vitro binding affinity of the mono-copper 
complex to both human and murine CXCR4 was determined via a CXCL12 stimulated calcium flux 
signalling assay and the IC50 value was determined to be 8 nM (human CXCR4), whereas the free 
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chelator precursor CB-Bicyclam displayed no measurable activity in this assay (>2 M) 
(Supplemental Fig. 4). Similar results were observed for murine CXCR4 with an IC50 value of 2 nM 
for CuCB-Bicyclam in murine CXCL12 binding assay (Supplemental Fig. 5). 
Radiochemistry, Purification and Stability 
Radiochemical synthesis of 64Cu-CuCB-Bicyclam was carried out by heating CB-Bicyclam 
with preformed 64Cu-Cu(OAc)2 and monitoring via radio-TLC (Supplemental Fig. 3). Upon full 
incorporation (40-50 minutes) the crude complex was purified from excess CB-Bicyclam using 
semi-preparative HPLC to give decay corrected isolated radiochemical yields of 69 ± 5% with a 
total synthesis time of 120 minutes and a specific activity of 7.15 GBq/mol. The LogP value was 
determined to be -2.38 ± 0.18. 64Cu-CuAMD3100 was synthesized and analysed following 
literature procedures (28). In vitro acid stability was measured to indicate comparative stability 
between tracers by incubating in 6 M HClO4 for 3 hours at 37oC. Identical radio-TLC methods were 
used to those used to analyse the radiosynthesis process and stability values of 92 ± 3% and 9 ± 
5% were determined for 64Cu-CuCB-Bicyclam and 64Cu-CuAMD3100 respectively.  
Receptor Expression and 64Cu-CuCB-Bicyclam Radioligand Binding In Vitro 
CXCR4 surface expression levels were determined by fluorescence-activated cell sorting 
for U87 (human CXCR4low) and U87.CXCR4 (human CXCR4high) cells (4,000 vs 148,000 
receptors/cell respectively) (Fig. 1). Radioligand binding experiments showed similar ratios to the 
expression level for the binding of the tracer (0.66 ± 0.56 and 20.22 ± 5.78% applied dose for U87 
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(CXCR4low) and U87.CXCR4 (CXCR4high) cells respectively) (Fig. 1). Pre-incubation of U87.CXCR4 
(CXCR4high) cells with Cu2CB-Bicyclam (IC50 = 3 nM) decreased binding of 64Cu-CuCB-Bicyclam by 
89%, consistent with high specific uptake.  
PET/CT Studies on Tumor Bearing Mice 
Dynamic PET/CT studies carried out on U87 (human CXCR4low) and U87.CXCR4 (human 
CXCR4high) xenograft-bearing mice demonstrated significantly higher uptake in human CXCR4high 
vs CXCR4low tumors after administration of 64Cu-CuCB-Bicyclam (9.6 ± 0.7 MBq), with SUVmax 
values of 7.36 ± 1.77% vs. 0.80 ± 0.14%  at 80-90 minutes post-injection (Fig. 2). Tumor-to-muscle 
ratios at 90 min after injection were 23.6 ± 2.7 for U87.CXCR4 (CXCR4high) and 3.0 ± 0.5 for U87 
(CXCR4low) tumors. Uptake was also seen in the kidneys and liver. Pre-injection of 10 mg/kg Cu2-
CB-Bicyclam 60 minutes before scanning reduced U87.CXCR4 (CXCR4high) tumor and liver uptake 
by >90%. See Supplemental Figures 6 and 7 for all scan data and further analysis. 
Ex Vivo Analysis of CXCR4 Expression 
CXCR4 expression in U87.CXCR4 (CXCR4high) and U87 (CXCR4low) tumors and murine liver 
was confirmed ex vivo by a combination of western blot, immunohistochemistry and qPCR 
(Supplemental Fig. 8; Supplemental Table 1). 
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Biodistribution and Tracer Stability Studies in Immunocompetent Mice 
Biodistribution studies were carried out using CD1-IGS mice at 90 minutes to determine 
the effect of a functional immune system on tracer distribution (Fig.3). Low uptake (<2 %ID/g) 
was noted in all organs except kidney (8.11 %ID/g) and organs known to express CXCR4 (spleen 
(4.71 %ID/g), lung (2.89 %ID/g) and liver (13.77 %ID/g)). Urine was analysed from a separate 
cohort of animals injected with 64Cu-CuCB-Bicyclam and 64Cu-CuAMD3100 pre-sacrifice. 64Cu-
CuCB-Bicyclam was >90% intact whilst only <10% of 64Cu-CuAMD3100 remained intact in the 
urine. 
Using murine liver CXCR4-dependent uptake of 64Cu-CuCB-Bicyclam as a readout, the in 
vivo affinities/ residence times of Cu2CB-Bicyclam, CuCB-Bicyclam, AMD3100 and AMD3465 were 
compared. Doses were administered 60 minutes prior to tracer administration and animals were 
sacrificed at several timepoints post-injection to provide tissue for biodistribution. Consistent 
with PET imaging in CD-1 Nude mice, pre-dosing with the Cu2CB-Bicyclam significantly reduced 
tracer uptake in liver (3.40 vs 13.77 %ID/g, p<0.05), spleen (0.48 vs 4.71 %ID/g, p<0.01) and lungs 
(1.06 vs 2.89 %ID/g, p<0.05) at 60 minutes but not 12 hours; similar results were seen using CuCB-
Bicyclam. No significant decrease in liver uptake was seen when animals were pre-injected with 
AMD3100 or AMD3465 at any timepoint. 
  




This study reports a high-affinity CXCR4-specific PET imaging agent (64Cu-CuCB-Bicyclam) 
which binds selectively and with high stability to both human and murine variants of the CXCR4 
receptor. Although 64Cu-CuCB-Bicyclam has potential as a clinical diagnostic PET imaging agent 
for oncology, it also represents a useful tool for the interrogation of CXCR4 expression levels over 
time in genetically engineered/immunocompetent pre-clinical models, useful in the investigation 
of CXCR4 targeting synergy with immunomodulatory therapies (49). 
Unlike AMD3100 and AMD3465, the labelling precursor CB-Bicyclam has CXCR4 affinity 
of > 2 μM due to the alkylation of the secondary amines disrupting the hydrogen bonding 
potential. The mono-copper species CuCB-Bicyclam has a higher affinity to the CXCR4 receptor 
than both AMD3100 and CuAMD3100 but lower than our previously described bis-copper species 
(Cu2CB-Bicyclam). However, it is likely to be sufficient for imaging studies and has the advantage 
of a precursor with >100 fold lower receptor affinity. Copper-64 radiolabelling was carried out 
using the minimum concentration required for full radiometal incorporation. We chose to purify 
64Cu-CuCB-Bicyclam from unreacted CB-Bicyclam using semi-prep HPLC for these experiments. 
 Radioligand binding experiments using U87.CXCR4 (CXCR4high) and U87 (CXCR4low) cells 
showed specific binding, with binding correlating well with quantified surface expression levels 
of CXCR4. In addition, in vitro binding could be blocked using the higher affinity complex Cu2CB-
Bicylam. In vivo PET/CT imaging using human CXCR4 U87.CXCR4 (CXCR4high) and U87 (CXCR4low) 
tumor-bearing mice mirrored the in vitro binding results, with selective high uptake in CXCR4high 
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tumors at 90 minutes post-injection. In vivo specificity was confirmed using a blocking dose of 
the higher affinity Cu2CB-Bicyclam, which reduced CXCR4high tumor uptake by >90%.   
As seen in previous studies utilising copper-64 labelled macrocycles for CXCR4 imaging, 
moderate liver uptake was seen on PET imaging using 64Cu-CuCB-Bicyclam. This uptake was 
reduced after blocking with Cu2CB-Bicyclam (5 mg/kg) to a comparable extent as that of CXCR4high 
tumors, suggesting specific binding to CXCR4. This compares to previous studies, where very high 
doses of AMD3100 (50 mg/kg) were used for blocking (33). Murine liver expression of CXCR4 was 
confirmed after ex vivo disaggregation of tumor or liver at the protein level via FACS and 
immunohistochemistry. Further experiments demonstrated that >90% of urine radioactivity was 
intact 64Cu-CuCB-Bicyclam, whereas the majority of activity from 64Cu-CuAMD3100 injected 
animals was in the form of free copper-64 ions. Acid stability assays (6 M HClO4) showed similar 
profiles for stability. These data are consistent with in vitro studies, demonstrating that cyclam 
copper(II) complexes which do not possess either structural reinforcement or coordinating arms 
have rapid binding kinetics but low stability in competition experiments (31,50,51). This data 
confirms both the insufficient stability of any non-bridged/ non-functionalized cyclam based 
copper(II) complex for in vivo PET imaging applications and also the higher stability of cross-
bridged cyclam structures.   
Further biodistribution studies were carried out using immunocompetent mice, to study 
the effect of blocking with various CXCR4 antagonists on the uptake of 64Cu-CuCB-Bicyclam. As 
expected, liver uptake of the tracer could be blocked by administration of either the higher 
affinity Cu2CB-Bicyclam or CuCB-Bicyclam at 60 minutes prior to tracer administration. However, 
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tracer uptake could not be blocked by the lower affinity CXCR4 antagonists; AMD3100 and 
AMD3465 (Fig. 3 and Supplemental Table 2). This could be explained by shorter (i.e. < 60 minute) 
receptor residence times for the unbridged cyclam compounds and/or displacement of 
AMD3100 or AMD3465 from CXCR4 by the higher affinity 64Cu-CuCB-Bicyclam compound (30). 
Whilst the development of therapeutic agents targeting CXCR4 was not the focus of this study, 
the high stability, high affinity and appropriate biodistribution of 64Cu-CuCB-Bicyclam makes the 
exploration of the identical radioactive and non-radioactive analogues as an 
imaging/chemotherapeutic pair of interest. The copper-67 derivative is of interest to investigate 
a radionuclide theranostic approach (52), assuming that the CXCR4 related liver uptake in 
humans is lower than in mice. 
CONCLUSION 
In this study we have developed a copper-64 labelled configurationally restricted 
azamacrocyclic CXCR4 antagonist with high affinity and stability and with favourable 
biodistribution characteristics. 64Cu-CuCB-Bicyclam is the first CXCR4 targeted PET imaging agent, 
with suitable characteristics for routine imaging studies, which binds to both the human and 
murine CXCR4 receptor variants. This allows wider pre-clinical assessment of the role of CXCR4 
in syngeneic tumor models and in immunocompetent models. It will also be useful for translation 
to other animal models of disease where imaging of the endogenous CXCR4 receptor is required. 
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KEY POINTS 
Question: The goal of this study is to develop a configurationally restricted azamacrocyclic 
compound as a high affinity and high stability copper-64 radiotracer for imaging CXCR4 
chemokine receptor expression in mice and in humans. 
Pertinent Findings: The radiotracer 64Cu-CuCB-Bicyclam binds with high affinity to both murine 
and human CXCR4. The compound retains the copper-64 radiolabel and is excreted intact, with 
blocking studies in vivo showing significant reduction in uptake in liver, spleen and human 
CXCR4 expressing tumour. 
 
Translational implications: 64Cu-CuCB-Bicyclam is an appropriate tracer for studies of murine 
CXCR4 expression in mouse models and can be translated for use in humans. 
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Figure 1 - In vitro assessment of 64Cu-CuCB-Bicyclam (A) Comparative affinity values vs. CXCL12 determined 
by calcium flux assay, (B) Chemical structures of 64Cu-CuAMD3100 and 64Cu-CuCB-Bicyclam (C) FACS 
determination of CXCR4 expression and (D) Binding of 64Cu-CuCB-Bicyclam on U87 (human CXCR4low) and 
U87.CXCR4 (human CXCR4high) expressing cell lines. 
  




Figure 2 – In vivo PET/CT evaluation of 64Cu-CuCB-Bicyclam. (A) Fused PET-CT maximum intensity 
projections at 70-90 mins post-injection from CD1 mice bearing U87-CXCR4 (n=3), U87 (n=3) and 
U87.CXCR4 block (n=2). Animals were injected with 9.6 ± 0.7 MBq of 64Cu-CuCB-Bicyclam. Blocking dose 
of 5 mg/Kg of Cu2CB-Bicyclam given 1 hour prior to 64Cu-CuCB-Bicyclam injection where indicated. Arrows 
denote position of tumor and liver. (B) Dynamic tumor time activity for showing uptake of 64Cu-CuCB-
Bicyclam in  tumor (top) and liver (bottom) during 90 minutes. Data represent mean uptake of n=2-3 
animals ± SEM. * U87.CXCR4 vs U87, P<0.01; **Block vs naïve, P<0.01. See Supplemental Figure 6 and 7 
for all images at 70-90 mins and time activity curves for bladder, kidney and vena cava.  
 
  






Figure 3 - Assessment of in vivo uptake of 64Cu-CuCB-Bicyclam after blocking with a range of CXCR4 
antagonists. Biodistribution of selected tissues from CD1-IGS mice pre-administered with 5 mg/Kg of 
Cu2CB-Bicyclam, CuCB-Bicyclam, AMD3100 or AMD3465 60 minutes (top) and 12 hours (bottom) before 
64Cu-CuCB-Bicyclam injection. Tissue was harvested 90 minutes after tracer administration (n=4). *Block 
vs naïve, P<0.05   
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